Stock Market Reviews

GKOS (Glaukos Corporation) News

Get the latest news, insights, and market updates on GKOS (Glaukos Corporation). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
  GKOS appears well-positioned for long-term growth as iDose TR adoption accelerates and Epioxa secures FDA approval, although reimbursement and execution risks remain.
  Dec 29, 2025 - $GKOS
• Glaukos Announces Participation in J.P. Morgan Healthcare Conference
  ALISO VIEJO, Calif., December 16, 2025--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 4:30 p.m. PT in San Francisco, CA.
  Dec 16, 2025 - $GKOS
• Glaukos (NYSE:GKOS) shareholders have earned a 34% CAGR over the last three years
  The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But in contrast you can...
  Dec 7, 2025 - $GKOS
• Inogen (INGN) Down 0.6% Since Last Earnings Report: Can It Rebound?
  Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
  Dec 5, 2025 - $GKOS
• Sudo Biosciences Appoints Paul Bavier as Chief Legal Counsel
  CARMEL, Ind. & LONDON, December 04, 2025--Sudo Biosciences Appoints Paul Bavier as Chief Legal Counsel
  Dec 4, 2025 - $GKOS
• Idexx (IDXX) Up 1.5% Since Last Earnings Report: Can It Continue?
  Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
  Dec 3, 2025 - $GKOS
• Glaukos (GKOS) Up 20% Since Last Earnings Report: Can It Continue?
  Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
  Nov 28, 2025 - $GKOS
• Here's Why You Should Retain Glaukos Stock in Your Portfolio
  GKOS gains momentum from iDose TR's strong launch and a growing pipeline, though reimbursement hurdles pose challenges ahead.
  Nov 28, 2025 - $GKOS
• Should Glaukos’ Improved Results and Raised Outlook Prompt a Closer Look From GKOS Investors?
  Glaukos Corporation recently reported its third quarter 2025 results, showing sales of US$133.54 million and a net loss of US$16.23 million, marking a strong improvement from the previous year; in addition, the company raised its full-year 2025 revenue guidance to US$490–495 million and issued a new preliminary outlook for 2026 revenue of US$600–620 million. An important insight is that both quarterly and nine-month net losses were reduced by a substantial margin compared to the prior year,...
  Nov 9, 2025 - $GKOS
• Beaten Down by 35%-Plus: Analysts Say These 2 Oversold Stocks Are Poised to Turn the Corner
  The stock markets have been ripping this year, with investors buying into the bullish trend. However, some savvy investors are turning their attention to the other side of the tape – oversold stocks. Sure, beaten-down stocks are often beaten down for a reason. Still, analysts argue that some of these names have been punished too harshly, creating compelling entry points at discounted levels. With that backdrop in mind, we’ve used the TipRanks platform to pinpoint stocks that have taken steep hit
  Nov 5, 2025 - $GKOS